INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery

LA JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced  that CJ Barnum PhD, Head of Neurosciences will present data from the ongoing biomarker directed Phase Ib study of neuroinflammation in patients with Alzheimer’s disease.  The talk entitled, Phase 1b Study in AD Patients with Neuroinflammation?, will be given today at 11:20AM ET as part of this year’s virtual 21st

Click to view original post

Advertise With Us